<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00945451</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000639362</org_study_id>
    <secondary_id>CALACASS-CYBERTAXCIS</secondary_id>
    <secondary_id>INCA-RECF0941</secondary_id>
    <secondary_id>2008-A01104-51</secondary_id>
    <nct_id>NCT00945451</nct_id>
  </id_info>
  <brief_title>Stereotactic Radiosurgery in Treating Patients Undergoing Chemotherapy and Radiation Therapy For Stage III Non-Small Cell Lung Cancer</brief_title>
  <official_title>Study of Doses Escalation on Efficacy on Cyberknife After Docetaxel-Cisplatin Concomitant Radiotherapy for Non Small Cells Lung Cancer Stage III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Antoine Lacassagne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Antoine Lacassagne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Stereotactic radiosurgery can send x-rays directly to the tumor and cause less&#xD;
      damage to normal tissue. Giving stereotactic radiosurgery after docetaxel and cisplatin may&#xD;
      kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and the best dose of stereotactic&#xD;
      radiosurgery when given after docetaxel, cisplatin, and radiation therapy and to see how well&#xD;
      it works in treating patients with stage III non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluate the maximum tolerated dose of stereotactic radiosurgery in patients with&#xD;
           locally advanced non-small cell lung cancer undergoing concurrent chemoradiotherapy.&#xD;
           (Phase I)&#xD;
&#xD;
        -  Assess the response rate (complete and partial response) in these patients by RECIST&#xD;
           criteria. (Phase II)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the tolerability. (Phase I)&#xD;
&#xD;
        -  Assess the quality of life of these patients by QLQ-C30 v3. (Phase I)&#xD;
&#xD;
        -  Assess the overall and disease-free survival of these patients. (Phase II)&#xD;
&#xD;
        -  Assess progression-free survival of these patients. (Phase II)&#xD;
&#xD;
      OUTLINE: This is a multicenter, phase I dose escalation study of stereotactic radiosurgery&#xD;
      followed by a phase II study.&#xD;
&#xD;
      Patients receive docetaxel IV and cisplatin IV on days 1, 22, 43, 50, 57, and 64 in the&#xD;
      absence of disease progression or unacceptable toxicity. Beginning on day 43, patients&#xD;
      undergo concurrent radiotherapy to the mediastinum 5 days a week. Beginning 2-3 weeks after&#xD;
      chemoradiotherapy, patients undergo stereotactic radiosurgery on days 1, 3, and 5.&#xD;
&#xD;
      Quality of life is assessed by the QLQ-C30 v3 questionnaire at baseline, after radiosurgery,&#xD;
      and at 6 and 12 months after completion of study treatment.&#xD;
&#xD;
      After completion of study treatment, patients are followed up monthly for 6 months, every 3&#xD;
      months for 1 year, and then every 6 months for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 24, 2009</start_date>
  <completion_date type="Actual">November 17, 2016</completion_date>
  <primary_completion_date type="Actual">November 17, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (phase I)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate by RECIST (phase II)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>CyberKnife irradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CK</intervention_name>
    <description>Cyberknife Irradiation</description>
    <arm_group_label>CyberKnife irradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed non-small cell lung cancer&#xD;
&#xD;
               -  Locally advanced disease&#xD;
&#xD;
          -  No metastatic disease&#xD;
&#xD;
          -  Unable to undergo surgery after concurrent chemoradiotherapy&#xD;
&#xD;
          -  Must have 1-3 tumor target masses &lt; 5 cm in greatest diameter and separated by ≥ 2 cm&#xD;
             after concurrent chemoradiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
          -  Neutrophil &gt; 1.0 x 10^9/L&#xD;
&#xD;
          -  FEV_1 &gt; 30% of vital capacity&#xD;
&#xD;
          -  Vital capacity &gt; 25% of predicted value&#xD;
&#xD;
          -  DLCO &gt; 25% of predicted value&#xD;
&#xD;
          -  LVEF ≥ 35%&#xD;
&#xD;
          -  PT &gt; 80&#xD;
&#xD;
          -  aPTT &gt; 35 sec&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  Not under guardianship&#xD;
&#xD;
          -  No dyspnea related to NYHA class III-IV heart failure&#xD;
&#xD;
          -  No indirect signs of pulmonary arterial hypertension (pulmonary arterial systolic BP &gt;&#xD;
             45 mm Hg)&#xD;
&#xD;
          -  No pulmonary acceleration time &lt; 100 ms&#xD;
&#xD;
          -  No contraindication to fiducial insertion&#xD;
&#xD;
          -  No geographical, social, or psychological conditions that would interfere with medical&#xD;
             follow-up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Docetaxel and platinum-based drugs with concurrent irradiation allowed&#xD;
&#xD;
          -  No prior surgery or surgery after the first phase of treatment with concurrent&#xD;
             chemoradiotherapy&#xD;
&#xD;
          -  No prior irradiation to lung&#xD;
&#xD;
          -  No concurrent participation in another study trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-Yves Bondiau, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Antoine Lacassagne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>July 23, 2009</study_first_submitted>
  <study_first_submitted_qc>July 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2009</study_first_posted>
  <last_update_submitted>September 13, 2019</last_update_submitted>
  <last_update_submitted_qc>September 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage II non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

